The Use of an Inhaled Salt Solution to Treat Viral Lung Infections in Infants.
|ClinicalTrials.gov Identifier: NCT00151905|
Recruitment Status : Completed
First Posted : September 9, 2005
Last Update Posted : May 7, 2007
|Condition or disease||Intervention/treatment||Phase|
|Bronchiolitis||Drug: 3 % hypertonic saline||Phase 2 Phase 3|
Bronchiolitis is a common illness in infants and is associated with a significant morbidity. Standard therapy is controversial and largely ineffective; care is mostly supportive although nebulized medications continue to be commonly used. These medications are typically mixed with normal saline to produce a sufficient volume for efficient nebulization.
Inhaled hypertonic saline has been used to aid airway clearance in children with cystic fibrosis. It has also been used, in low dose, in two small studies in children with bronchiolitis. The current study is a randomized, double-blind, placebo-controlled, multi-center trial comparing frequent dosing with 3% hypertonic saline compared to normal saline in the treatment of infants hospitalized with bronchiolitis.
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||Nebulized Hypertonic Saline in the Treatment of Bronchiolitis in Infants|
|Study Start Date :||November 2003|
|Estimated Study Completion Date :||September 2006|
- Length of stay.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00151905
|Canada, British Columbia|
|Victoria General Hospital|
|Victoria, British Columbia, Canada|
|Kingston General Hospital|
|Kingston, Ontario, Canada, K7L 2V7|
|United Arab Emirates|
|Sheikh Khalifa Medical City|
|Abu Dhabi, United Arab Emirates, 51900|
|Principal Investigator:||Brian A Kuzik, MD, FRCP||Sheikh Khalifa Medical City|